 Five Prime Therapeutics NASDAQ:FPRX was upgraded by Zacks Investment Research from a hold rating to a buy rating in a report released on Wednesday, Zacks.com reports. The firm currently has a 5.00 target price on the biotechnology companys stock. Zacks Investment Researchs price objective would indicate a potential upside of 20.19 from the stocks current ... 